The administration of probiotics and synbiotics in immune compromised adults: is it safe?

@article{vandenNieuwboer2015TheAO,
  title={The administration of probiotics and synbiotics in immune compromised adults: is it safe?},
  author={Maurits van den Nieuwboer and Robert Jan Brummer and Francisco Guarner and Lorenzo Morelli and Michael D. Cabana and Elizabeth Claasen},
  journal={Beneficial microbes},
  year={2015},
  volume={6 1},
  pages={
          3-17
        }
}
This study aimed to systematically evaluate safety of probiotics and synbiotics in immune compromised adults (≥18 years). Safety was analysed using the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification, thereby providing an update on previous reports using the most recent available clinical data (2008-2013). Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected… 

Figures and Tables from this paper

Dealing with the remaining controversies of probiotic safety.

The rationale for using probiotics in the critically ill; what happened during the Dutch Pancreatitis trial; what are the known safety risks of probiotics based on the available data; and how standardisation in safety reporting can drive probiotic innovation are discussed.

Probiotics and Synbiotics Decrease Postoperative Sepsis in Elective Gastrointestinal Surgical Patients: a Meta-Analysis

The use of probiotic/synbiotic supplementation is associated with a significant reduction in the risk of developing postoperative sepsis in patients undergoing elective GI surgery.

The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation

This study provides preliminary evidence that administration of LBP is safe and feasible in children and adolescents undergoing HCT, and recommends the conduct of an approved randomized, controlled trial through Children’s Oncology Group.

Absence of adverse events in healthy individuals using probiotics--analysis of six randomised studies by one study group.

In conclusion, ingestion of probiotic supplementations containing LGG alone, or LGG in combination with L. rhamnosus Lc705, P. freudenreichii JS, B. breve 99, or B. lactis BB12 did not seem to cause AEs in young and elderly subjects in this analysis.

Probiotics for the Management of Infectious Diseases: Reviewing the State of the Art

Overall, research demonstrated a substantial interest in probiotics targeting infectious diseases, which was in line with reported unmet needs and global probiotics sales estimates, however, the declining rate of translation from patents to clinical trials indicates that there are some barriers obstructing the research process.

Probiotics in Autoimmune and Inflammatory Disorders

Several randomized controlled trials have now shown that microbial modification by probiotics may improve gastrointestinal symptoms and multiorgan inflammation in rheumatoid arthritis, ulcerative colitis, and multiple sclerosis.

Safety of Probiotics in Health and Disease

Probiotics to HIV-Infected Immunological Nonresponders: Altered Mucosal Immunity and Microbial Diversity Restricted to Ileum

Probiotics induced segment-specific changes in the terminal ileum but did not affect systemic CD4 counts in INRs and further clinical studies are warranted to recommend probiotics to INRs.
...

References

SHOWING 1-10 OF 117 REFERENCES

Probiotic and synbiotic safety in infants under two years of age.

Analysis of 57 clinical trials with probiotics and synbiotics in combination with eight follow-up studies indicate that probiotic administration to infants between 0 and 24 months is safe with regard to the evaluated strains in infants with a particular health status or susceptibility.

Probiotic, prebiotic, and synbiotic use in critically ill patients

The results of the PROPATRIA (Probiotics Prophylaxis in Patients with Predicted Severe Acute Pancreatitis) trial highlight the need for meticulous attention to safety monitoring.

Safety of Probiotics to Reduce Risk and Prevent or Treat Disease

There is a lack of assessment and systematic reporting of adverse events in probiotic intervention studies, and interventions are poorly documented, and the current literature is not well equipped to answer questions on the safety of probiotic interventions with confidence.

Clinical applications of probiotic agents.

  • J. Saavedra
  • Medicine
    The American journal of clinical nutrition
  • 2001
The benefits documented thus far are of varying degree and are most likely dependent on the number of agents, the dose, the dosing patterns, and the characteristics of the host and its underlying luminal microbial environment.

An update on the use and investigation of probiotics in health and disease

Progress in this area will be facilitated by optimising strain, dose and product formulations, including protective commensal species; matching these formulations with selectively responsive subpopulations; and identifying ways to manipulate diet to modify bacterial profiles and metabolism.

Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial

A significant increase in CD4+ T lymphocyte levels in the synbiotic group is shown, which could delay the initiation of antiretroviral therapy and decrease costs in countries with limited resources.

Synbiotics Decrease the Incidence of Septic Complications in Patients with Severe SIRS: A Preliminary Report

Analysis of fecal flora confirmed that patients with severe SIRS had significantly greater levels of beneficial Bifidobacterium, Lactobacillus, and total organic acids than those in the NS group, and the incidence of infectious complications was significantly lower in the S group than in theNS group.

Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials.

The present meta-analysis suggests that the administration of probiotics did not significantly reduce ICU or hospital mortality rates but did reduce the incidence of ICU-acquired pneumonia and ICU length of stay.

Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial

Although numerous uncertainties remain (type and the number of strains to use, delay and length of administration), and despite an acceptable safety profile, the daily prophylactic administration of probiotics cannot be encouraged in the critically ill patient.

Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection

Synbiotic treatment for 4 weeks can successfully augment the levels of probiotic species in the gut during chronic HIV-1 infection, and markers of systemic immune activation appear largely unchanged.
...